On Wednesday, IMRIS Inc (NASDAQ:IMRS)’s shares declined -17.24% to $0.0240.
IMRIS Inc (IMRS) declared that the Company received a letter May 26, 2015 from the NASDAQ Stock Market LLC (“Nasdaq”) stating that in accordance with Listing Rules 5101, 5110(b), and IM-5101-1, the Staff has determined that the Company’s securities will be delisted from The NASDAQ Stock Market. Accordingly, trading of the Company’s Common Shares will be suspended at the opening of business on June 4, 2015, and a Form 25-NSE will be filed with the Securities and Exchange Commission’s (the SEC), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. The Nasdaq staff determination was based on the following factors: the associated public interest concerns raised by the Company’s press release dated May 26, 2015 in which the Company declared it has filed for protection under Chapter 11 of the U.S. Bankruptcy Code; concerns regarding the residual equity interest of the existing listed securities holders; and concerns about the Company’s ability to sustain compliance with all requirements for continued listing on The Nasdaq Stock Market.
IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment.
Eli Lilly and Co (NYSE:LLY)’s shares dropped -0.15% to $77.83.
Eli Lilly and Co (LLY) will take part in the White House Forum on Antibiotic Stewardship where Elanco President Jeff Simmons will take part in a panel talk about. Co presently, Simmons is unveiling the company’s multi-faceted approach to combat the growing concern about antibiotic resistance. A summary of Simmons’ remarks follows:
In the next few decades, demand for animal protein will climb 60 percent[1] as population enhances and the global middle class expands by three billion people[2]. These numbers are important, because we’re already overusing the Earth’s resources, consuming about 1.5 times the natural resources we should use in a year[3]. Delivering safe, sufficient, affordable protein to feed the growing population has never been at greater risk.
The welfare of animals we rely upon to provide protein is also at risk. Recently, we have emerging diseases on every continent, counting the extreme of avian influenza right here in the United States. Beyond that – nearly 3 in 4 cattle experience symptoms of respiratory disease[4] at some point in their life and 1 in 6 dairy cattle experience mastitis[5] in their productive life. It is our industry’s responsibility to keep animals healthy and treat the ones that get sick while safeguarding antibiotics for future generations through responsible use. Ultimately, this is about One Health – not just animal health, but this work creates healthy food, ensures the health of people and protects the planet.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
At the end of Wednesday’s trade, Nevro Corp (NYSE:NVRO)‘s shares dipped -2.25% to $50.29.
Nevro Corp (NVRO) declared the pricing of an upsized underwritten public offering of its common stock at a public offering price of $51.00 per share, before underwriting discounts. The offering comprises of 1,764,705 shares to be sold by Nevro and 2,941,175 shares to be sold by certain of its stockholders, resulting in aggregate proceeds of about $90.0 million to Nevro and about $150.0 million to the selling stockholders, in each case before underwriting discounts and commissions and expenses payable by Nevro. In addition, Nevro granted the underwriters a 30-day option to purchase up to an additional 705,882 shares of common stock from Nevro.
The offering is predictable to close on or about June 8, 2015, subject to satisfaction of customary closing conditions.
J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering. Leerink Partners and JMP Securities are acting as co-managers.
Nevro Corp., a medical device company, develops and commercializes a neuromodulation platform for the treatment of chronic pain. It offers Senza system, a spinal cord stimulation system that delivers its proprietary HF10 therapy. The company was founded in 2006 and is headquartered in Menlo Park, California.
Take-Two Interactive Software, Inc. (NASDAQ:TTWO), ended its Wednesday’s trading session with 2.60% gain, and closed at $28.26.
Firaxis Games is a 2K studio. 2K is a publishing label of Take-Two Interactive Software, Inc. (TTWO).
2K and Firaxis Games recently declared that XCOM® 2, the sequel to the Game of the Year* award-winning strategy title XCOM®: Enemy Unknown, is presently in development for Windows-based PC. Developed by Firaxis Games, XCOM 2 transports players 20 years into the future, where humanity lost the war against the alien threat that has established a new world order. The secret paramilitary organization known as XCOM is largely forgotten, and must strike back to reclaim control of Earth and free mankind from the aliens’ rule. XCOM 2 is presently planned for release in November 2015. The game will also be coming to Mac and Linux via Feral Interactive.
In XCOM 2, the roles have been reversed, and XCOM is now the invading force. They are hampered by limited resources and must constantly evade the alien threat in their new mobile headquarters. Players must use a combination of firepower and stealth-like tactics to assist XCOM recruit soldiers and build a resistance network, while attempting to expose the evil alien agenda and save humanity. XCOM 2 will introduce gameplay features such as procedurally-generated levels, which will make each experience unique to the player, in addition to offer a much deeper level of modding support. Additionally, XCOM 2 will offer a variety of new content counting five updated soldier classes, raised soldier customization, more alien and enemy types, evolved tactical combat and more.
Take-Two Interactive Software, Inc. develops, publishes, and markets interactive entertainment for consumers worldwide. The company offers its products under the Rockstar Games and 2K labels. It develops and publishes action/adventure products under the Grand Theft Auto, Max Payne, Midnight Club, and Red Dead names through developing sequels; offering downloadable episodes, and content and currency; and releasing titles for smartphones and tablets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
